title: Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant.
abstract: Components of the natural anticoagulant system (NAS) and anticardiolipin antibodies were examined in 21 patients with lupus anticoagulant (LA), 13 of whom had past histories of thrombotic episodes. No relationship could be shown between the antigenic levels of protein C and S (PC, PS) and a history of thrombosis. Inhibition of the anticoagulant activity of activated protein C (APC) was observed using plasma from 20/21 patients when phospholipid vesicles were used as the surface for the coagulation reaction. This effect was not affected by the addition of PS. When platelet membranes were employed only 2/21 patients demonstrated inhibition of APC. Under the latter condition, PS functional activity was inhibited in 7/21 patients, six of whom had a past history of thrombosis. Reduced antithrombin III or heparin cofactor II levels were observed in a total of 4/21 patients and may have contributed to the development of thrombosis in three of these patients. Antibodies specifically directed against these proteins were not detected suggesting the possibility of an associated constitutional deficiency. Anticardiolipin antibodies, though elevated in 17/21 patients, did not serve as a useful marker for an increased risk of thrombosis, and the level did not correlate with inhibition of the activity of APC or PS. We conclude that the mechanism of thrombosis in patients with LA is multi-factorial. A subset of patients in whom LA specifically inhibits PS function may represent patients who are at significant risk from thrombosis.
authors.affiliation: Department of Medicine, Monash Medical School, Alfred Hospital, Victoria, Australia.
authors.forename: S C
authors.initials: SC
authors.lastname: Lo
authors.forename: H H
authors.initials: HH
authors.lastname: Salem
authors.forename: M A
authors.initials: MA
authors.lastname: Howard
authors.forename: M J
authors.initials: MJ
authors.lastname: Oldmeadow
authors.forename: B G
authors.initials: BG
authors.lastname: Firkin
mesh_terms: D000906:Antibodies / Q000032:analysis*; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000502:physiology*; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000276:immunology; D001779:Blood Coagulation Factors / Q000276:immunology* / Q000378:metabolism; D001798:Blood Proteins / Q000276:immunology; D002308:Cardiolipins / Q000276:immunology*; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional; D016682:Lupus Coagulation Inhibitor; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology; D011486:Protein C / Q000276:immunology; D018046:Protein C Inhibitor; D017293:Protein S
chemical_list: D000906:Antibodies; D001779:Blood Coagulation Factors; D001798:Blood Proteins; D002308:Cardiolipins; D006023:Glycoproteins; D016682:Lupus Coagulation Inhibitor; D011486:Protein C; D018046:Protein C Inhibitor; D017293:Protein S; D000990:Antithrombin III